Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Allarity Therapeutics Inc ALLR

Allarity Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing personalized cancer treatments. The Company is focused on development of stenoparib, a poly-ADP-ribose polymerase/Tankyrase inhibitor for advanced ovarian cancer patients, using its DRP companion diagnostic for patient selection in the ongoing phase 2 clinical trial, NCT03878849. It has in-licensed the... see more

Recent & Breaking News (NDAQ:ALLR)

Allarity Therapeutics Inc Is Being Sued For Violating Securities Laws And Affected Investors Are Urged To Contact The Schall Law Firm

ACCESS Newswire October 10, 2024

ALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud Lawsuit

PR Newswire October 10, 2024

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics

Newsfile October 10, 2024

Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement

GlobeNewswire October 10, 2024

ALLR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Allarity Therapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!

ACCESS Newswire October 10, 2024

The Schall Law Firm Encourages Shareholder Participation In A Securities Fraud Case Against Allarity Therapeutics, Inc.

ACCESS Newswire October 9, 2024

ALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

PR Newswire October 9, 2024

ALLR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Allarity Therapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

ACCESS Newswire October 9, 2024

Allarity Therapeutics Inc Is Being Sued For Securities Law Violations And Affected Investors Are Urged To Assist The Schall Law Firm

ACCESS Newswire October 8, 2024

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics

Newsfile October 8, 2024

ALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud Lawsuit

PR Newswire October 8, 2024

ALLR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Allarity Therapeutics, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

ACCESS Newswire October 8, 2024

The Schall Law Firm Encourages Shareholder Participation In A Securities Fraud Case Against Allarity Therapeutics, Inc.

ACCESS Newswire October 7, 2024

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Allarity Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALLR

Newsfile October 7, 2024

ALLR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Allarity Therapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

ACCESS Newswire October 7, 2024

Allarity Therapeutics Inc Is Being Sued For Securities Law Violations And Affected Investors Are Urged To Contact The Schall Law Firm

ACCESS Newswire October 6, 2024

ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Allarity Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALLR

Newsfile October 6, 2024

ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics

Newsfile October 6, 2024

ALLR STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Allarity Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

ACCESS Newswire October 6, 2024

The Schall Law Firm Encourages Shareholders To Join A Securities Fraud Case Against Allarity Therapeutics, Inc.

ACCESS Newswire October 5, 2024